Published in final edited form as:

Radiother Oncol. 2015 November ; 117(2): 213–216. doi:10.1016/j.radonc.2015.09.016.

Breast Cancer Following Spinal Irradiation for a Childhood Cancer: A Report from the Childhood Cancer Survivor Study

Chaya S. Moskowitz,

Memorial Sloan Kettering Cancer Center, New York NY 10017

Jyoti Malhotra,

Rutgers Cancer Institute of New Jersey, New Brunswick NJ 08901

Joanne F. Chou,

Memorial Sloan Kettering Cancer Center, New York NY 10017

Suzanne L. Wolden,

Memorial Sloan Kettering Cancer Center, New York NY 10021

Rita E. Weathers,

University of Texas MD Anderson Cancer Center, Houston TX 77030

Marilyn Stovall,

University of Texas MD Anderson Cancer Center, Houston TX 77030

Gregory T. Armstrong,

St. Jude Children's Research Hospital, Memphis TN 38105

Wendy M. Leisenring,

Fred Hutchinson Cancer Research Center, Seattle WA 98109

Joseph P. Neglia,

University of Minnesota Masonic Cancer Center, Minneapolis MN 55455

Leslie L. Robison, and

St. Jude Children's Research Hospital, Memphis TN 38105

Kevin C. Oeffinger

Memorial Sloan Kettering Cancer Center, New York NY 10017

Summary

It has been suggested that pediatric patients treated with spinal irradiation may have an elevated risk of breast cancer. Among a cohort of 363 long-term survivors of a pediatric central nervous system tumor or leukemia treated with spinal irradiation, there was little evidence of an increased breast cancer risk.

Corresponding author: Chaya S. Moskowitz, PhD, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY 10017, Phone: 646-888-8232, Fax: 646-735-0010, moskowc1@mskcc.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

craniospinal irradiation; late effects; secondary breast cancer

Introduction

Spinal irradiation is essential for cure for many children with central nervous system (CNS) tumors, including medulloblastoma. It was also used until the 1980's to treat some children with leukemia. While breast cancer is not commonly thought to be a late sequela of spinal irradiation, we are not aware of studies that specifically address this question. Multiple studies assessing the occurrence of second neoplasms in leukemia and CNS tumor survivors report very few instances of breast cancer despite studying thousands of patients (with a maximum median follow-up of 18.7 years). [1–8] None of these studies, however, present enough details to evaluate whether these breast cancers are occurring specifically among survivors treated with spinal irradiation.

Materials and Methods

We analyzed participants in the Childhood Cancer Survivor Study (CCSS), a cohort of 5-year survivors of childhood cancer diagnosed before age 21 years between 1970–1986 at one of 26 participating institutions. Participants and data collection methods were described previously. [9, 10] The institutional review board at each institution approved the CCSS protocol. Informed consent was obtained from all participants or their parents. We focus on female survivors of a pediatric CNS tumor or leukemia who were treated with spinal irradiation but with no other radiation field near breast tissue (women also treated with high abdominal fields or total body irradiation were excluded). Delivered spinal irradiation doses were abstracted from medical records. Average breast doses were calculated using radiation treatment parameters as previously described. [11] To summarize the average breast dose across all participants, we present a weighted average of the average nipple dose across cohort participants. Radiation doses to the left and right ovaries were also estimated. The right and left ovary doses were equivalent in all but four women, and the average is presented. The Cyclophosphamide Equivalent Dose (CED) was used to quantify cumulative alkylating agent exposure and was calculated as has been described previously. [12]

We estimated the relative risk of breast cancer with standardized incidence ratios (SIRs) using age- and calendar-year-specific incidence rates in the U.S. of invasive and in-situ carcinoma from the Surveillance, Epidemiology, and End Results (SEER) program. Only the first primary breast cancer diagnosis is included. CCSS participants were considered at risk of breast cancer starting five years after their childhood cancer diagnosis until a diagnosis of breast cancer, death, or date of last follow-up. All analyses were done in Stata 12.1 for Windows (StataCorp LP, College Station TX).

Results

Among 363 survivors of leukemia and CNS tumors treated with spinal irradiation, the median age at diagnosis of the primary childhood cancer was five years (range= [0, 19]).

Among participants still alive, the median follow-up was 27 years (range= [10, 38]). The median attained age was 35 years (range= [10, 53]); 36 years among all leukemia survivors and 33 years among CNS tumor survivors. The majority of the participants in this sub-cohort were survivors of either (a) acute lymphoblastic leukemia (ALL) (n=184) or (b) medulloblastoma or primitive neuroectodermal tumor (PNET) (n=125). The median attained age of ALL survivors was 33 years (range=[6,52]), and the median follow-up among ALL survivors still alive was 27 years (range=[10,38]). The median attained age of medulloblastoma or PNET survivors was 33 years (range=[8,54]), and the median follow-up among those survivors still alive was 26 years (range= [11,38]). Additional characteristics of these participants are presented in Table 1.

Three women were diagnosed with breast cancer. One was diagnosed with invasive ductal carcinoma in the left breast, quadrant unknown, at 31 years of age after receiving 23 Gy Cobalt-60 craniospinal radiotherapy for acute lymphoblastic leukemia (ALL) at 13 years of age; average dose to the breast was 0.61 Gy. A second woman was diagnosed with ductal carcinoma in-situ in the upper outer quadrant of the right breast at age 41 years after receiving 18 Gy craniospinal radiotherapy with Cobalt-60 for ALL at age 15; average breast dose was 0.67 Gy. Both had no known family history of breast cancer. The third woman was diagnosed with invasive ductal carcinoma at age 41 years, location unknown, after receiving 25 Gy craniospinal radiotherapy with 4 MeV for a leukemia at age 12; average dose to the breast was 0.49 Gy. Her family history was unknown.

Leukemia survivors had lower delivered doses of spinal irradiation than CNS tumor survivors, a median of 18 Gy (range=[1.5, 41.8]) compared with a median of 34.53 Gy (range=[4.8, 65.0]) for CNS tumor survivors (Figure 1), although their estimated doses to the breast were similar, an average of 1.1 Gy compared with 1.5 Gy for leukemia and CNS tumor survivors, respectively. The SIR was 2.4 (95% CI: 0.8 to 7.5) in all women treated with spinal irradiation, and 3.8 (95% CI: 1.2 to 11.7) in leukemia survivors.

CNS tumor survivors also tended to be treated with higher doses of alkylating agents than were leukemia survivors. Among the 74 (44%) CNS tumor survivors who were treated with alkylators, the median CED was 11,435 mg/m² (range=[1111.1, 32,517.1]). Among the 98 (50%) leukemia survivors treated with alkylators, the median CED was 6,756.8 mg/m² (range=[102.7, 49,380.4]). Ovarian radiation doses were similar in the two groups, a median of 3.3 Gy for CNS tumor survivors (range=[0.01,34.0]) compared with 2.8 Gy for leukemia survivors (range=[0.02,34.7]).

Discussion

Several recent papers have used simulation and modeling strategies based on the estimated radiation dose to the breast to suggest there may be an increased breast cancer risk after spinal irradiation with conventional photon therapy for a pediatric malignancy particularly when compared to irradiation with proton therapy. These analyses have been taken to indicate that there may be a substantially elevated breast cancer risk after photon therapy [14, 15], that proton therapy may significantly reduce this risk although the risk reduction may depend on the method of proton beam delivery [15–17], and that early breast cancer

screening might be considered in women treated with high doses of spinal irradiation using conventional photon therapy. [16]

For women without an increased breast cancer risk, the U.S. Preventive Services Task Force recommends biennial screening mammograms beginning at age 50 years. [18] Others, including the American Cancer Society and the National Comprehensive Cancer Network, recommend annual screening mammograms beginning at age 40 years. [19, 20] In contrast, women treated with chest radiotherapy for a childhood cancer have one of the highest risks of breast cancer among any population. [21–25] Breast cancer surveillance guidelines recommend specialized surveillance for women treated with 20 Gy of chest radiation (craniospinal irradiation is not mentioned in these guidelines) with annual screening starting at age 25 years or eight years after radiotherapy, whichever occurs last. [26–28] In comparison to this high risk population where we previously estimated an SIR of 21.9 (95% CI 19.1–25.2)[23], here we found a more modestly elevated risk of breast cancer in leukemia survivors treated with spinal irradiation and no evidence of an increased risk of breast cancer in CNS tumor survivors.

One might hypothesize that the CNS tumor survivors might have received more ovarian toxic therapy which may in some way have reduced their risk of breast cancer. As noted above, 44% of the CNS tumor survivors and 50% of leukemia survivors were treated with at least one alkylating agent. Of those treated with an alkylator, the CED was modestly higher for CNS tumor survivors (11,435 mg/m²) than the leukemia survivors (6,756 mg/m²). Neither group had particularly high dose alkylating agent chemotherapy. Ovarian radiation doses were fairly similar across groups: of 3.3 Gy for CNS tumor survivors compared with 2.8 Gy for leukemia survivors. Thus, there does not appear to be a substantive difference between the two groups, with respect to ovarian toxic therapy, to explain the differences in risk of breast cancer risk.

Thus, our results suggest that spinal irradiation for treatment of a pediatric malignancy may not be associated with an increased breast cancer risk, particularly at a young age, when early breast cancer screening might be considered. Ongoing follow-up is needed, though, before definitive conclusions can be drawn. The increased risk we observed in leukemia survivors is noteworthy and may be attributable to other risk modifiers such as genetic factors. [29] For instance, leukemia and breast cancer are both cancer types known to be associated with a p53 mutation and Li-Fraumeni Syndrome (LFS). [30] Notably, however, while CNS tumors are similarly found in individuals with LFS, [30, 31] there were no breast cancer cases among this group. Nevertheless, genetic contributors to breast cancer in this population warrant future study.

Our conclusions are limited by a small sample size and the cohort's young age. With only 21% of the cohort 40 years, we have insufficient data to comment on the association between spinal irradiation and breast cancer risk after age 40. It is possible that with additional follow-up and a larger sample size, an excess risk may become evident.

In summary, we found little evidence supporting early breast cancer screening targeting women exposed to spinal irradiation for a childhood cancer.

Acknowledgments

This work was supported by the National Cancer Institute at the National Institutes of Health (R01 CA136783 to C.S.M., R01 CA134722 and K05 CA160724 to K.C.O., U24 CA55727 to G.T.A., and the Core Grant P30 CA008748 to Memorial Sloan Kettering Cancer Center). The funding source had no role in the study design, data collection, analysis and interpretation, nor in the writing of the manuscript.

References

1. Bhatia S, Sather HN, Pabustan OB, Trigg ME, Gaynon PS, Robison LL. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. *Blood*. 2002; 99:4257–64. [PubMed: 12036851]
2. Broniscer A, Ke W, Fuller CE, Wu J, Gajjar A, Kun LE. Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. *Cancer*. 2004; 100:2246–52. [PubMed: 15139071]
3. Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. *JAMA*. 2007; 297:1207–15. [PubMed: 17374815]
4. Maule M, Scelo G, Pastore G, Brennan P, Hemminki K, Tracey E, et al. Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. *J Natl Cancer Inst*. 2007; 99:790–800. [PubMed: 17505074]
5. Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. *J Natl Cancer Inst*. 2001; 93:618–29. [PubMed: 11309438]
6. Neglia JP, Meadows AT, Robison LL, Kim TH, Newton WA, Ruymann FB, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. *N Engl J Med*. 1991; 325:1330–6. [PubMed: 1922234]
7. Olsen JH, Moller T, Anderson H, Langmark F, Sankila R, Tryggvadottir L, et al. Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. *J Natl Cancer Inst*. 2009; 101:806–13. [PubMed: 19470947]
8. Tsui K, Gajjar A, Li C, Srivastava D, Broniscer A, Wetmore C, et al. Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therap. *Neuro-Oncology*. In press.
9. Leisenring WM, Mertens AC, Armstrong GT, Stovall MA, Neglia JP, Lanctot JQ, et al. Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study. *J Clin Oncol*. 2009; 27:2319–27. [PubMed: 19364957]
10. Robison LL, Mertens AC, Boice JD, Breslow NE, Donaldson SS, Green DM, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. *Med Pediatr Oncol*. 2002; 38:229–39. [PubMed: 11920786]
11. Stovall M, Weathers R, Kasper C, Smith SA, Travis L, Ron E, et al. Dose reconstruction for therapeutic and diagnostic radiation exposures: Use in epidemiological studies. *Radiation research*. 2006; 166:141–57. [PubMed: 16808603]
12. Green DM, Nolan VG, Goodman PJ, Whitton JA, Srivastava D, Leisenring WM, et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. *Pediatric blood & cancer*. 2014; 61:53–67. [PubMed: 23940101]
13. Surveillance, Epidemiology, and End Results (SEER) Program,. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2010 Sub (1973–2008) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969–2009 Counties,. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; released April 2011.
14. Brodin NP, Vogelius IR, Maraldo MV, Munck af Rosenschold P, Aznar MC, Kiil-Berthelsen A, et al. Life years lost--comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. *Cancer*. 2012; 118:5432–40. [PubMed: 22517408]

15. Mu X, Bjork-Eriksson T, Nill S, Oelfke U, Johansson KA, Gagliardi G, et al. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study. *Acta Oncol.* 2005; 44:554–62. [PubMed: 16165914]
16. Kumar RJ, Zhai H, Both S, Tochner Z, Lustig R, Hill-Kayser C. Breast cancer screening for childhood cancer survivors after craniospinal irradiation with protons versus x-rays: a dosimetric analysis and review of the literature. *Journal of pediatric hematology/oncology.* 2013; 35:462–7. [PubMed: 23892352]
17. Athar BS, Paganetti H. Comparison of second cancer risk due to out-of-field doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans. *Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology.* 2011; 98:87–92. [PubMed: 21159398]
18. U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Annals of internal medicine.* 2009; 151:716–26. W-236. [PubMed: 19920272]
19. American Cancer Society. American Cancer Society Guidelines for the Early Detection of Cancer. Atlanta, GA: American Cancer Society; 2009. Accessed at <http://www.cancer.org/healthy/findcancerearly/cancerscreeningguidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer> on [August 4, 2014]
20. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, v.1.2014. National Comprehensive Cancer Network; 2014.
21. Guibout C, Adjadj E, Rubino C, Shamsaldin A, Grimaud E, Hawkins M, et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. *J Clin Oncol.* 2005; 23:197–204. [PubMed: 15625374]
22. Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. *J Clin Oncol.* 2007; 25:1489–97. [PubMed: 17372278]
23. Moskowitz CS, Chou JF, Wolden SL, Bernstein JL, Malhotra J, Novetsky Friedman D, et al. Breast cancer after chest radiation therapy for childhood cancer. *J Clin Oncol.* 2014; 32:2217–23. [PubMed: 24752044]
24. Taylor AJ, Winter DL, Stiller CA, Murphy M, Hawkins MM. Risk of breast cancer in female survivors of childhood Hodgkin's disease in Britain: a population-based study. *International journal of cancer Journal international du cancer.* 2007; 120:384–91. [PubMed: 17066449]
25. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. *JAMA.* 2003; 290:465–75. [PubMed: 12876089]
26. Children's Oncology Group. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Version 3.0. 2008. [Accessed July 21, 2014]
27. Mulder RL, Kremer LC, Hudson MM, Bhatia S, Landier W, Levitt G, et al. Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *The lancet oncology.* 2013; 14:e621–9. [PubMed: 24275135]
28. Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. *Annals of internal medicine.* 2010; 152:444–55. W144–54. [PubMed: 20368650]
29. Henderson TO, Moskowitz CS, Onel K, Bradbury AR, Novetsky Friedman D, Chou JF, et al. Breast cancer in childhood cancer survivors not treated with chest-directed radiation in the Childhood Cancer Survivor Study (CCSS). *J Clin Oncol.* 2014; 32(5s suppl):abstr 10009.
30. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. *Oncogene.* 2001; 20:4621–8. [PubMed: 11498785]

31. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. *J Clin Oncol*. 2009; 27:1250–6. [PubMed: 19204208]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1. Distribution of doses of spinal irradiation. The delivered doses of spinal irradiation are shown separately by childhood cancer diagnosis. The delivered doses for the three women diagnosed with breast cancer are denoted with an X.

Table 1
 Characteristics of CNS tumor and leukemia survivors treated with spinal irradiation

Characteristic	Total (N=363)		CNS tumor survivors* (N=168)		Leukemia survivors** (N=195)	
	No.	%	No.	%	No.	%
Age at diagnosis of primary cancer, years						
0–4	166	45.7	56	33.3	110	56.4
5–11	133	36.6	78	46.4	55	28.2
12 and older	64	17.6	34	20.2	30	15.4
Year of diagnosis of primary cancer						
1970–1974	115	31.7	16	9.5	99	50.8
1975–1979	74	20.4	42	25.0	32	16.4
1980–1986	174	47.9	110	65.5	64	32.8
Dose of spinal irradiation, Gy						
Less than 19	107	29.5	4	2.4	103	52.8
19–24	101	27.8	21	12.5	80	41.0
25–35	99	27.3	90	53.6	9	4.6
36+	56	15.4	53	31.6	3	1.5
Race						
White, non-Hispanic	320	88.2	148	88.1	172	88.2
Minorities	42	11.6	20	11.9	22	11.3
Unknown	1	0.3	0	0	1	0.5
CED (mg/m²)						
0	191	60.1	94	64.4	97	56.4
>0–3,999	34	10.7	6	4.1	28	16.2
4000–7,999	22	6.9	7	4.8	15	8.7
8,000+	71	22.3	39	26.7	32	18.6
Average ovarian irradiation dose (cGy)						
0	9	2.5	0	0	9	4.6
1–99	34	9.5	9	5.5	25	12.9
100–999	273	76.0	139	84.2	134	69.1
1000–1999	26	7.2	9	5.5	17	8.8

Characteristic	Total (N=363)		CNS tumor survivors* (N=168)		Leukemia survivors** (N=195)	
	No.	%	No.	%	No.	%
2000+	17	4.7	8	4.9	9	4.6
Vital Status						
Alive	282	77.7	130	77.4	152	78.0
Deceased	81	22.3	38	22.6	43	22.0
Follow-up, years ^{***}						
Less than 20 years	84	23.1	42	25.0	42	21.5
20+ years	279	76.9	126	75.0	153	78.5
Age at analysis, years ^{****}						
Under 25	82	22.6	40	23.8	42	21.5
25–39	218	60.1	106	63.1	112	57.4
40+	63	17.4	22	13.1	41	21.0

* Diagnoses of CNS tumor survivors consist of medulloblastoma or primitive neuroectodermal tumor (n=125), astrocytoma (n=8), and other CNS tumor (n=35).

** Diagnoses of leukemia survivors consist of acute lymphoblastic leukemia (n=184), acute myeloid leukemia (n=2), and other leukemia (n=9).

CEID = Cyclophosphamide equivalent dose (information is missing on n=45 participants)

Minimum ovarian irradiation dose missing on n=4 participants

*** Evaluated in participants still alive at last contact.

**** Defined as the age at breast cancer diagnosis, death, or last contact.